Search clinical trials for: Myelodysplastic syndrome

Total 37291 results

Indiana University

Withdrawn

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia, Adult | Bone Marrow Transplant Complications

United States
Kyowa Kirin, Inc.

Terminated

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

Italy, Spain, Belgium, France, Turkey, Austria, Brazil, Netherlands, Australia, Finland, Russian Federation, Sweden, Canada, United States
Aprea Therapeutics

Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia or Myelodysplastic Syndromes

United States
Pfizer

Completed

A Study Of PF-04449913 In Select Hematologic Malignancies

Hematologic Malignancies

United States, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (DHODH)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United Kingdom, France, Korea, Republic of, Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Neoplasms | Myelodysplastic Syndromes | Non-Hodgkin Lymphoma | Solid Tumor, Adult

United States, Spain, Israel, Germany, Canada
University of Chicago

Completed

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Classical Hodgkin Lymphoma | B-cell Non-Hodgkin Lymphoma

United States
Advanced BioDesign

Active, not recruiting

First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY)

Myelodysplastic Syndromes | Acute Myeloid Leukemia, Adult

France
Sclnow Biotechnology Co., Ltd.

Suspended

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

China
Groupe Francophone des Myelodysplasies

Active, not recruiting

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France, Italy
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Acute Lymphoid Leukemia (ALL)

United States
UNC Lineberger Comprehensive Cancer Center

Completed

Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

Hematologic Neoplasms

United States
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

Lower-risk Myelodysplastic

Japan
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
University Health Network, Toronto

Active, not recruiting

Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Relapsed Cancer | Refractory Cancer

Canada
The First Affiliated Hospital of Soochow University

Enrolling by invitation

Follow-up Study of ICUS and CCUS Patients

Myelodysplastic Syndromes

China
Rigshospitalet, Denmark
Odense University Hospital; University of Copenhagen; Imperial College London; University... and other collaborators

Active, not recruiting

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies (EVITA)

Myelodysplastic Syndromes | Cytopenia | Chronic Myelomonocytic Leukemia-1

Denmark, United States
Seoul National University Hospital
Merck Sharp & Dohme LLC

Completed

Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients

Myelodysplastic Syndromes | Fungal Infection | Aplastic Anemia

Korea, Republic of
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Suspended

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia

United States
TJ Biopharma Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndromes(MDS)

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

United States
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (APPOINT-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China, Germany, Singapore, Korea, Republic of, Italy, United Kingdom, Malaysia, France
Novartis Pharmaceuticals

Withdrawn

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Forma Therapeutics, Inc.

Completed

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States, Spain, Korea, Republic of, Australia, Canada, Germany, France, United Kingdom, Italy
Qianfoshan Hospital

Completed

Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide

Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma

China
Nkarta Inc.

Active, not recruiting

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

MDS | AML, Adult | Relapsed/Refractory AML | Refractory Myelodysplastic Syndromes

United States
Washington University School of Medicine
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

SARS-CoV-2 Donor-Recipient Immunity Transfer

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | COVID-19 Infection | Accelerated Phase... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) (1703/1801)

Lymphoma | Acute Leukemia | Myelodysplasia | Chronic Myelogenous Leukemia (CML)

United States
Haukeland University Hospital
Novartis

Withdrawn

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (DefeHEMY)

Myelodysplastic Syndromes | Hemochromatosis

Norway
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Australia, Canada, Italy, Norway, Spain, Sweden, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Precancerous/Nonmalignant Condition
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, Japan, Taiwan, Germany, France, United Kingdom, Spain, Korea, Republic of, Czechia, Brazil, Netherlands, United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Myelodysplastic Syndrome With Excess Blasts-1 | Myelodysplastic Syndrome/Acute Myeloid Leukemia

Canada, United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid... and other conditions

United States
Roswell Park Cancer Institute

Active, not recruiting

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Acute Myeloid Leukemia | Polycythemia Vera | Myelofibrosis | Chronic Myelomonocytic Leukemia | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Sickle Cell Disease | Myelodysplastic Syndrome | Plasma Cell Myeloma | Chronic Granulomatous... and other conditions

United States
Jennifer Eva Selfridge

Suspended

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Colorectal Cancer | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Plasma Cell Myeloma | Hematologic Malignancy | Rectum Cancer | Myeloproliferative Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT

Acute Leukemia | Myelodysplastic Syndrome

United States
Guenther Koehne

Suspended

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Myelodysplastic Syndromes | Graft Vs Host Disease | Graft-versus-host-disease

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Enrolling by invitation

Pathogenesis of Hematologic Malignancies

Lymphoproliferative Disorders | Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia

United States
NYU Langone Health
Perlmutter Cancer Center

Completed

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Myelodysplastic Syndromes

United States

Search clinical trials for: Myelodysplastic syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations